In this episode of the 2 Minute Medicine® Podcast, we explore major advances in precision medicine, beginning with the Phase 3 TALAPRO-3 trial demonstrating improved outcomes with talazoparib combined with enzalutamide in metastatic prostate cancer. We review new evidence from the COBRRA trial comparing apixaban and rivaroxaban, highlighting a significantly improved bleeding profile without loss of efficacy. The episode then examines Eli Lilly’s investigational triple-agonist retatrutide, which is showing unprecedented weight loss and glycemic control in patients with type 2 diabetes. Finally, we discuss a recent FDA warning issued to Novo Nordisk regarding delayed adverse event reporting and what this means for clinicians as GLP-1 therapies continue to expand rapidly in clinical practice.